Seven pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
NuPathe Inc. (PATH) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. For more information, get Portfolio Grader’s complete analysis of PATH stock.
This week, GW Pharmaceuticals PLC Sponsored ADR (GWPH) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
Watson Pharmaceuticals (WPI) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Paratek Pharmaceuticals Inc (PRTK) gets a higher grade this week, advancing from a B last week to an A. For more information, get Portfolio Grader’s complete analysis of PRTK stock.
Pain Therapeutics, Inc. (PTIE) improves from a B to an A rating this week. Pain Therapeutics develops safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers. For more information, get Portfolio Grader’s complete analysis of PTIE stock.
Cardiome Pharma (CRME) shows solid improvement this week. The company’s rating rises from a C to a B. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.
AbbVie, Inc.’s (ABBV) ratings are looking better this week, moving up to a B from last week’s C. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
